Hcc
![Pembrolizumab Keytruda](https://www.msdconnect.ph/wp-content/uploads/sites/98/2022/11/pembrolizumab_keytruda_tcm5001-863657-5.jpg)
![](https://www.msdconnect.ph/wp-content/uploads/sites/98/2022/11/womens-ca-1-banner-3.png)
KEYNOTE-224:
Open-label study in patients with HCC, previously treated with sorafenib, an anti-angiogenic TKI
N=104 participants
The median duration of follow-up – 12·3 months (IQR 7·6–15·1)1
Objective Response1
![](https://www.msdconnect.ph/wp-content/uploads/sites/98/2022/11/hepatocellular-carcinoma-4.png)
KEYNOTE-224:
Open-label study in patients with HCC, previously treated with sorafenib, an anti-angiogenic TKI
N=104 participants
The median duration of follow-up – 12·3 months (IQR 7·6–15·1)1